Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: A meta-analysis

Current Medical Research and Opinion

Volumn 28, Issue 6, 2012, Pages 969-977

  Han, Steven ^a   Iglay, Kristy ^a   Davies, Michael J ^a   Zhang, Qiaoyi ^a   Radican, Larry ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antihyperglycemic therapy; Compliance; Diabetes; Efficacy; Meta analysis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; HEMOGLOBIN A1C; METFORMIN; PHENFORMIN; SULFONYLUREA;

ANTIDIABETIC ACTIVITY; COCHRANE LIBRARY; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG EFFICACY; EMBASE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; MEDLINE; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; POPULATION SIZE; REVIEW;

ALGORITHMS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HUMANS; HYPOGLYCEMIC AGENTS; MEDICATION ADHERENCE; TREATMENT OUTCOME;

EID: 84862563647     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.684045     Document Type: Review

References (39)

1. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hypergly-cemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
2. Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract 2011;65:314-22
3. Rozenfeld Y, Hunt JS, Plauschinat C, et al. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care 2008;14:71-5
4. Rhee MK, Slocum W, Ziemer DC, et al. Patient adherence improves glycemic control. Diabetes Educ 2005;31:240-50
5. Lawrence DB, Ragucci KR, Long LB, et al. Relationship of oral antihypergly-cemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program. J Manag Care Pharm 2006;12:466-71
6. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166:1836-41
7. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 2004;27:2149-53
8. Hansen RA, Farley JF, Droege M, et al. A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglita-zone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005. Clin Ther 2010;32:1308-19
9. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-19
10. Barner JC. Adherence to oral antidiabetic agents with pioglitazone and met-formin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy. Clin Ther 2011;33:1281-8
11. Hutchins V, Zhang B, Fleurence RL, et al. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin 2011;27:1157-68
12. Blonde L, Wogen J, Kreilick C, et al. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab 2003;5:424-31
13. Cheong C, Barner JC, Lawson KA, et al. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther 2008;30:1893-907
14. Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 2008;23:611-14
15. Thayer S, Arondekar B, Harley C, et al. Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea. Ann Pharmacother 2010;44:791-9
16. Schernthaner G. Fixed-dose combination therapies in the management of hyperglycaemia in Type 2 diabetes: an opportunity to improve adherence and patient care. Diabet Med 2010;27:739-43
17. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:W65-94
18. Higgins JPT, Deeks JJ. Selecting studies and collecting data. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons, 2008
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88
20. Deeks JJ, Higgins JPT, Altman DG. Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons, 2008
21. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60
22. Bax L, Yu LM, Ikeda N, et al. A systematic comparison of software dedicated to meta-analysis of causal studies. BMC Med Res Methodol 2007;7:40
23. Bax L, Yu LM, Ikeda N, et al. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol 2006;6:50
24. Bax L, Yu LM, Ikeda N, et al. MIX: Comprehensive free software for meta-analysis of causal research data (Version 1.7). Available at http://mix-for-meta-analysis (last accessed December 1, 2011)
25. Patel BV, Leslie RS, Aranda GA. Retrospective comparison of compliance to fixed-dose combination versus single agent combination therapy for the treatment of diabetes (abstract). ISPOR 12th Annual Meeting, Arlington, VA, USA, 2008
26. Leslie RS, Gwadry-Sridhar F, Patel BV, Sanchez-Trask L. Retrospective comparison of compliance and persistence to fixed-dose combination versus single agent combination therapy for the treatment of diabetes (abstract). Academy of Managed Care Pharmacy Annual Meeting, San Antonio, TX, USA, 2009
27. Gwadry-Sridhar F, Leslie RS, Patel BV, et al. Understanding predictors of compliance in fixed-dose combination vs. loose-dose combination therapy for treatment of type 2 diabetes (abstract). Diabetes 2010;59(Suppl 1):A346
28. Gwadry-Sridhar F, Leslie RS, Patel B, et al. Influence of previous medication compliance on future compliance in patients with type 2 diabetes (abstract). Diabetes 2010;59(Suppl 1):A54
29. Melikian C, White TJ, Vanderplas A, et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002;24:460-7
30. Brook L, Kleinman KL, Wingenbach D, et al. Medication possession ratio and health benefit cost comparisons in type 2 diabetes patients using fixed-and loose-dose thiazolidinedione combination products (abstract). Diabetes 2008;57(Suppl 1):1214-P
31. Delea T, Arondekar B, Kartashov A, et al. Add-on therapy with rosiglitazone (RSG)/metformin (MET) as a fixed-dose combination (FDC) vs. RSG plus MET or RSG plus sulfonylurea (SU) as separate pills (SP): retrospective study of outcomes and costs (abstract). Diabetes 2007;56(Suppl 1):2200-PO
32. Sterne JAC, Egger M, Moher D. Addressing reporting biases. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons, 2008
33. Raptis AE, Tountas N, Yalouris AG, et al. Comparative study of the therapeutic effects of glibenclamide or the fixed combination of glibenclamide-phenfor-min with those of gliclazide or chlorpropamide. Acta Diabetol Lat 1990;27:11-22
34. Duckworth W, Marcelli M, Padden M, et al. Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets. J Manag Care Pharm 2003;9:256-62
35. Guidance for Industry: Diabetes mellitus-Developing drugs and therapeutic biologics for treatment and prevention. Feb. 2008. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM071624.pdf (last accessed December 1, 2011)
36. Vanderpoel DR, Hussein MA, Watson-Heidari T, et al. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. Clin Ther 2004;26:2066-75
37. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55:399-407
38. Juday T, Gupta S, Grimm K, et al. Factors associated with complete adherence to HIV combination antiretroviral therapy. HIV Clin Trials 2011;12:71-8
39. Balu S, Simko RJ, Quimbo RM, et al. Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence. Curr Med Res Opin 2009;25:2765-75